Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2016

01-07-2016 | Research Article

Clinical significance of cellular and acellular mucin pools in rectal carcinoma following preoperative chemoradiotherapy

Authors: J. A. Cienfuegos, J. Baixauli, F. Rotellar, J. Arredondo, J. J. Sola, L. Arbea, C. Pastor, J. L. Hernández-Lizoáin

Published in: Clinical and Translational Oncology | Issue 7/2016

Login to get access

Abstract

Background and objectives

The standard treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (CRT) followed by surgery. Pathological findings remain the most significant prognostic factor. The presence of mucin pools and their prognostic significance is a controversial issue. The aim of this study was to analyze the incidence of cellular and acellular mucin pools and their clinical significance.

Methods

Four-hundred and forty-six consecutive prospectively collected specimens from patients with LARC treated with long-course preoperative CRT and surgery were analyzed. Kaplan–Meier analysis was performed.

Results

Mucin pools were present in 182 specimens (40.8 %); 66 (14.7 %) were acellular, and viable tumor cells were identified in 116 (26 %). The complete pathological response rate was 13.5 % (60 of 446). With a median follow-up of 79.0 months, the 5- and 10-year disease-free survivals for patients with acellular and cellular mucin pools were 81.5, 78.1, 63.7 and 61.2 %, respectively (p ≤ 0.026). The presence of cells in the colloid response to treatment was associated with a 17.8 and 16.9 % decrease in 5- and 10-year disease survival vs. acellular colloid response.

Conclusions

Our results suggest that cellular mucin pools are an indicator of an aggressive phenotype and harbingers of a worse prognosis.
Literature
1.
Julien LA, Thorson AG. Current neoadjuvant strategies in rectal cancer. J Surg Oncol. 2010;101(321):326.
2.
Reynold M, Niland J, ter Veer A, Milne D, Bekaii-Saab T, Cohen SJ, et al. Neoadjuvant radiotherapy use in locally advanced rectal cancer at NCCN member institutions. J Natl Compr Cancer Netw. 2014;12:235–43.
3.
Mamon HJ, Tepper JE. Combination chemoradiation therapy: the whole is more than the sum of the parts. J Clin Oncol. 2014;32:367–9.CrossRefPubMed
4.
5.
Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5.CrossRefPubMed
6.
Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926–33.CrossRefPubMed
7.
Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol. 2014;32:1554–62.CrossRefPubMed
8.
Shia J, Guillem JG, Moore HG, Tickoo SK, Qin J, Ruo L, et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol. 2004;28:215–23.CrossRefPubMed
9.
Quah HM, Chou JF, Gonen M, Shia J, Schrag D, Saltz LB, et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer. 2008;113:57–64.CrossRefPubMed
10.
Bouzourene H, Bosman FT, Matter M, Coucke P. Predictive factors in locally advanced rectal cancer treated with preoperative hyperfractionated and accelerated radiotherapy. Hum Pathol. 2003;34:541–8.CrossRefPubMed
11.
Agarwal A, Chang GJ, Hu CY, Taggart M, Rashid A, Park IJ, et al. Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. Cancer. 2013;119:4231–41.CrossRefPubMed
12.
Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. 1997;12:19–23.CrossRefPubMed
13.
Castro EB, Rosen PP, Quan SH. Carcinoma of large intestine in patients irradiated for carcinoma of cervix and uterus. Cancer. 1973;31:45–52.CrossRefPubMed
14.
Nagtegaal I, Gaspar C, Marijnen C, Van De Velde C, Fodde R, Van Krieken H. Morphological changes in tumour type after radiotherapy are accompanied by changes in gene expression profile but not in clinical behaviour. J Pathol. 2004;204:183–92.CrossRefPubMed
15.
Ooki A, Akagi K, Yatsuoka T, Asayama M, Hara H, Yamamoto G, et al. Inverse effect of mucinous component on survival in stage III colorectal cancer. J Surg Oncol. 2014;110:851–7.CrossRefPubMed
16.
von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbrouke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–7.CrossRef
17.
Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK. AJCC cancer staging atlas: A companion to the seventh Editions of the AJCC Cancer Staging Manual and Handbook. 2nd ed. New York: Springer; 2012.CrossRef
18.
Aristu JJ, Arbea L, Rodriguez J, Hernández-Lizoáin JL, Sola JJ, Moreno M, et al. Phase I–II trial of concurrent capecitabine and oxaliplatin with preoperative intensity-modulated radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2008;71:748–55.CrossRefPubMed
19.
Arbea L, Martinez-Monge R, Diaz-Gonzalez JA, Moreno M, Rodríguez J, Hernández JL, et al. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. Int J Radiat Oncol Biol Phys. 2012;83:587–93.CrossRefPubMed
20.
Arredondo J, Baixauli J, Beorlegui C, Arbea L, Rodríguez J, Sola JJ, et al. Prognosis factors for recurrence in patients with locally advanced rectal cancer preoperatively treated with chemoradiotherapy and adjuvant chemotherapy. Dis Colon Rectum. 2013;56:416–21.CrossRefPubMed
21.
Jass JR, O’Brien J, Riddell RH, Snover DC. Association of Directors of Anatomic and Surgical Pathology. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma: Association of Directors of Anatomic and Surgical Pathology. Am J Clin Pathol. 2008;129:13–23.CrossRefPubMed
22.
Ruo L, Tickoo S, Klimstra DS, Minsky BD, Saltz L, Mazumdar M, et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg. 2002;236:75–81.CrossRefPubMedPubMedCentral
23.
Shia J, McManus M, Guillem JG, Leibold T, Zhou Q, Tang LH, et al. Significance of acellular mucin pools in rectal carcinoma after neoadjuvant chemoradiotherapy. Am J Surg Pathol. 2011;35:127–34.CrossRefPubMed
24.
Lim SB, Hong SM, Yu CS, Hong YS, Kim TW, Park JH, et al. Prevalence and clinical significance of acellular mucin in locally advanced rectal cancer patients showing pathologic complete response to preoperative chemoradiotherapy. Am J Surg Pathol. 2013;37:47–52.CrossRefPubMed
25.
Colon and rectum. In: American Joint Committee on Cancer, ed. AJCC cancer staging manual. 7th ed. New York: Springer; 2010. p. 145–61.
26.
Washington MK, Berlin J, Branton P, Burgart LJ, Carter DK, Fitzgibbons PL, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009;133:1539–51.PubMedPubMedCentral
27.
Rullier A, Laurent C, Vendrely V, Le Bail B, Bioulac-Sage P, Rullier E. Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal carcinoma. Am J Surg Pathol. 2005;29:602–6.CrossRefPubMed
28.
Smith KD, Tan D, Das P, Chang GJ, Kattepogu K, Feig BW, et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg. 2010;251:261–4.CrossRefPubMed
29.
de Campos-Lobato LF, Dietz DW, Stocchi L, Vogel JD, Lavery IC, Goldblum JR, et al. Clinical implications of acellular mucin pools in resected rectal cancer with pathological complete response to neoadjuvant chemoradiation. Colorectal Dis. 2012;14:62–7.CrossRefPubMed
30.
Cienfuegos JA, Rotellar F, Baixauli J, Beorlegui C, Sola JJ, Arbea L, et al. Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery. Ann Surg Oncol. 2015;22:916–23.CrossRefPubMed
31.
Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241:829–36 (discussion 836-8).CrossRefPubMedPubMedCentral
32.
Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688–96.CrossRefPubMed
33.
Smith FM, Wiland H, Mace A, Pai RK, Kalady MF. Clinical criteria underestimate complete pathological response in rectal cancer treated with neoadjuvant chemoradiotherapy. Dis Colon Rectum. 2014;57:311–5.CrossRefPubMed
Metadata
Title
Clinical significance of cellular and acellular mucin pools in rectal carcinoma following preoperative chemoradiotherapy
Authors
J. A. Cienfuegos
J. Baixauli
F. Rotellar
J. Arredondo
J. J. Sola
L. Arbea
C. Pastor
J. L. Hernández-Lizoáin
Publication date
01-07-2016
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 7/2016
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1422-8

Other articles of this Issue 7/2016

Clinical and Translational Oncology 7/2016 Go to the issue

Brief Research Article

Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer

Research Article

Can tumor regression grade influence survival outcome in ypT3 rectal cancer?

Research Article

Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer

Research Article

Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer

Research Article

Landscape of early clinical trials for childhood and adolescence cancer in Spain

Research Article

Compliance to radiation therapy of head and neck cancer patients and impact on treatment outcome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits